De Novo
DEN230061: allay Nerve Cap
FDA De Novo · tulavi therapeutics · decided Jul 16, 2024
Key facts
| De Novo number | DEN230061 |
|---|---|
| Device name | allay Nerve Cap |
| Applicant | tulavi therapeutics |
| Product code | SBG |
| Date received | Sep 12, 2023 |
| Decision date | Jul 16, 2024 |
| Decision | granted (DENG) |
| FDA classification | Class II |
| Review panel | Neurology |
| FEI number | 3027562169 |
At a glance
- 1–9 Later 510(k)s citing this De Novo
- 1–9 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
- No Decision summary on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About De Novo classification requests
The De Novo pathway classifies novel low- to moderate-risk devices that have no legally marketed predicate; each granted request creates a new classification regulation and product code.
Source: U.S. Food and Drug Administration (FDA), De Novo database · Source date: